Schizophrenia Spectrum and Other Psychotic Disorders Clinical Trial
Official title:
Effect of Acceptance and Commitment Therapy-based Lifestyle Counselling Programme for People With Early Psychosis on Physical Activity: A Pilot Randomised Controlled Trial
This pilot randomized controlled trial aims to determine the feasibility, acceptability and preliminary effects of an Acceptance and Commitment Therapy-based Lifestyle Counselling Programme (ACT-LCP) on the physical and psychosocial health outcomes of patients with early psychosis over a 12-week follow-up.
Background: Three-quarters of deaths in psychotic patients are caused by Cardiometabolic Diseases (CMD), including but not limited to cardiac disease, diabetes, and stroke. Globally, the average life expectancy of a psychotic patient is 10 to 20 years shorter than the average life expectancy of those without a psychotic diagnosis. Research has supported that early intervention on lifestyle and cardiometabolic risks is essential to prevent the occurrence of CMD. This study will integrate the framework of Acceptance and Commitment Therapy and Self-Determination Therapy with a healthy-lifestyle intervention programme cultivating autonomous motivation of psychotic patients to live healthier. In addition, the acceptance and mindfulness-based part of ACT would increase the patient's awareness to psychological struggles. While many studies reviewed the ACT's effectiveness in improving mental health and functioning outcomes as well as enhancing physical activity and maintenance of weight reduction for individuals without mental illness, the use of the ACT-based lifestyle intervention in psychotic patients with the framework of Self-Determination Therapy has not even been examined. Objectives: To determine the feasibility, acceptability and preliminary effects of an Acceptance and Commitment Therapy-based Lifestyle Counselling Programme (ACT-LCP) on the physical and psychosocial health outcomes of patients with early psychosis over a 12-weeks follow-up period. Hypotheses to be tested: When compared with the Control Group receiving standard care and lifestyle education talk, more participants in the ACT-LCP Group will be physically active, defined as participating in at least 150 minutes/week of moderate to vigorous-intensity of physical activity, at 1-week and at 12-weeks post-intervention. The ACT-LCP group will report improvements in healthy dietary intake, autonomous motivation, psychological flexibility, mental status and quality of life. Design and subjects: An assessor-blind randomized controlled trial with two-arm, repeated-measures design; 72 Cantonese-speaking patients with early psychosis. Study Instruments: Validated questionnaires, accelerometer-based wristband activity tracker Intervention: One ACT-LCP, including 5-weekly sessions (2 hours/session) of group therapy, one 'booster' session to be held at 1-month afterwards, followed by 2-weekly telephone follow-ups. Main outcome measure: Prevalence of being physically active, as measured by the accelerometer-based wristband activity tracker at 12 weeks post-intervention. Data analysis: The assessment of acceptability and feasibility of the ACT-LCP will be assessed by examining the recruitment rate, the attrition rate, the completion of after-session homework and post programme focus group interviews. Generalized estimating equations with covariate adjustments will be used to examine the preliminary effects of ACT-LCP. Expected results: Patients with early psychosis will become more autonomously motivated and more psychologically flexible to continue regular healthy lifestyle behaviours, leading to improvements in health outcomes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
| Enrolling by invitation |
NCT03090490 -
10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
|
N/A | |
| Completed |
NCT03323437 -
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
|
Phase 4 | |
| Recruiting |
NCT06423651 -
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
|
N/A | |
| Completed |
NCT06040944 -
Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
|
||
| Recruiting |
NCT04452175 -
Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With Schizophrenia
|
N/A | |
| Completed |
NCT03501888 -
Cognitive Behavior Therapy for Patients With Psychoses.
|
N/A | |
| Completed |
NCT05601063 -
Ascertaining Diagnosis Classification With Elicited Speech
|
||
| Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
| Completed |
NCT03955549 -
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial
|
Phase 3 | |
| Completed |
NCT03235908 -
Copeptin in Outcome Prediction of an Acute Psychotic Episode
|
||
| Recruiting |
NCT05622201 -
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
|
Phase 2 | |
| Recruiting |
NCT05491486 -
Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia
|
N/A | |
| Recruiting |
NCT04104347 -
Metacognitive Training and Insight in Schizophrenia
|
N/A | |
| Recruiting |
NCT05664594 -
State Representation in Early Psychosis - Project 4
|
N/A | |
| Recruiting |
NCT05538832 -
Remote State Representation in Early Psychosis
|
Early Phase 1 | |
| Completed |
NCT02220504 -
3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals
|
N/A | |
| Completed |
NCT04665401 -
Personalizing Interventions Using Real-World Interactions
|
N/A | |
| Recruiting |
NCT03919760 -
Early Psychosis Intervention - Spreading Evidence-based Treatment
|